LEQVIO (Inclisiran) – Innovative Long-Acting Cholesterol-Lowering Therapy
Just Two Injections a Year for Lasting Control of Bad Cholesterol
High cholesterol—especially elevated low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol)—is a common cardiovascular risk factor in Hong Kong. If left unmanaged, it can lead to atherosclerosis, heart disease, or stroke. Many people struggle to reach target LDL-C levels even with maximum tolerated statin therapy, or they experience side effects like muscle pain or liver concerns that make daily pills hard to stick with.
LEQVIO (generic name: inclisiran), developed by Novartis, is a breakthrough small interfering RNA (siRNA) therapy. It targets a specific gene (PCSK9) in the liver, reducing PCSK9 protein production. This increases the number of LDL receptors on liver cells, dramatically improving the clearance of bad cholesterol from the blood. Unlike daily oral medications, LEQVIO offers a long-lasting effect: after two initial injections (on Day 1 and at 3 months), maintenance doses are needed only every 6 months—meaning just two injections per year to keep LDL-C under control.
Clinical studies show LEQVIO can reduce LDL-C by about 50% or more, providing significant additional benefits even when added to statins. This makes it especially valuable for high-risk patients who need stronger or more convenient cholesterol management.
Who Is LEQVIO Suitable For?
- Adults with primary hypercholesterolemia (including non-familial or heterozygous familial hypercholesterolemia).
- Mixed dyslipidemia.
- Particularly those with atherosclerotic cardiovascular disease (ASCVD) history (e.g., previous heart attack, stroke, or peripheral artery disease) or heterozygous familial hypercholesterolemia (HeFH).
- It can be used alongside diet and maximally tolerated statin therapy, or alone/in combination with other lipid-lowering treatments if statins are not tolerated or contraindicated.
Not recommended for children/adolescents, pregnant or breastfeeding women, people with severe liver or kidney impairment, or those allergic to inclisiran or its components.
How LEQVIO Is Administered
LEQVIO is given as a subcutaneous injection (284 mg per dose) by a healthcare professional, typically in the abdomen, upper arm, or thigh.
- Starting phase: One injection on Day 1, followed by another at Day 90 (3 months).
- Maintenance: One injection every 6 months thereafter.
No need for daily pills—ideal for busy lifestyles or those who forget medications. Before injection, allow the syringe to reach room temperature (do not shake it). The process is quick and straightforward.
Key Benefits
- Powerful, sustained LDL-C reduction—helping more patients meet international cardiovascular guidelines.
- Generally well-tolerated; most common side effects are mild injection-site reactions (redness, pain, rash), which usually resolve quickly. Other occasional effects include joint pain, urinary tract infections, diarrhea, or chest pain.
- No major known drug interactions with other lipid-lowering therapies (but always inform your doctor of all medications).
Availability in Hong Kong
LEQVIO is registered and available in Hong Kong as a prescription-only medicine. It can be prescribed by registered doctors (e.g., cardiologists, endocrinologists, or family physicians) and obtained through private clinics, hospitals, or pharmacies. Some private health insurance plans may offer partial coverage (depending on your policy), but it is typically self-pay or partially reimbursed. It is not widely subsidized in public hospitals (Hospital Authority) at present—check with your doctor for the latest status.
Lifestyle Tips to Maximize Results
Medication is only part of the picture—the best outcomes come from a holistic approach:
- Follow a heart-healthy diet (e.g., Mediterranean-style: plenty of vegetables, fruits, whole grains, healthy fats; reduce refined carbs, saturated/trans fats).
- Aim for at least 150 minutes of moderate exercise per week.
- Maintain a healthy weight, quit smoking, and limit alcohol.
- Regularly monitor blood lipids, liver/kidney function, and overall cardiovascular risk.
Frequently Asked Questions
- Really just two injections a year? Yes—the siRNA mechanism provides effects that last over 6 months, supported by strong clinical evidence.
- Can it replace statins? Usually used as an add-on; it can be used alone if statins aren’t suitable, but always under medical guidance.
- Are side effects serious? Most are mild and temporary; serious issues are rare.
- What if I miss an injection? If within 3 months of the due date, get it as soon as possible and adjust the schedule; if longer, consult your doctor to restart or revise the plan.
Disclaimer
This page is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. LEQVIO is a prescription medicine that must be assessed and prescribed by a registered doctor. Individual results, side effects, and suitability vary, and there may be risks. Do not self-medicate or purchase without a prescription. If you have health concerns, consult a doctor immediately and refer to the latest official guidelines (e.g., from the Hong Kong Department of Health Drug Office or your physician). All risks are borne by the user.
Want to Learn More?
Talk to your family doctor, cardiologist, or lipid specialist to discuss if LEQVIO is right for you. Many private healthcare providers in Hong Kong can offer assessments and injections.